MedTrace Logo

An Ascending Dose Study of BMS-986259 to Study Safety in Healthy Participants

NCT04008992 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2021-04-09

No results posted yet for this study

Summary

A Randomized double blind, placebo controlled study of BMS-986259 to evaluate the safety and effectiveness of the drug amongst different conditions and populations.

Conditions

  • Healthy Participants

Interventions

DRUG

BMS-986259

Single and Multiple ascending dose from Dose 1 to Dose 5

OTHER

Placebo

Placebo matching BMS-986259

DIAGNOSTIC_TEST

P-Aminohippurate

Diagnostic Agent

DIAGNOSTIC_TEST

Iohexol

Diagnostic Agent

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-18
Primary Completion
2021-01-04
Completion
2021-01-04

Countries

  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04008992 on ClinicalTrials.gov